Fatty acid derivative anticonvulsants

Introduction
Fatty acid derivative anticonvulsants are a subclass of antiepileptic drugs (AEDs) structurally related to or derived from fatty acids, primarily the short-chain branched fatty acid valproic acid and its derivatives. These agents are widely used in the treatment of epilepsy, bipolar disorder, and migraine prophylaxis, and they exert broad-spectrum anticonvulsant activity. The pharmacologic effects arise not only from their influence on ion channels and neurotransmitter balance but also from epigenetic and neuroprotective mechanisms, particularly those involving histone deacetylase inhibition (HDACi).

1. Core Drugs in the Class: Fatty Acid Derivative Anticonvulsants

A. Valproic Acid (VPA)

• Brand names: Depakene, Depacon (IV formulation)

B. Divalproex Sodium

• Brand names: Depakote, Depakote ER

• A compound of sodium valproate and valproic acid in a 1:1 molar ratio; designed for delayed or extended release

C. Sodium Valproate

• Used more commonly in Europe and Asia

• Available as injectable or oral formulation

D. Valnoctamide and Related Derivatives (experimental)

• Structural analogs under investigation for epilepsy and mood disorders

These drugs are interconverted in vivo and share the same active moiety—valproate.

---

2. Mechanism of Action

Valproate’s anticonvulsant action is multimodal, which contributes to its broad-spectrum efficacy:

A. GABAergic Modulation

• Inhibits GABA transaminase and succinate semialdehyde dehydrogenase → increases GABA levels

• Enhances GABAergic neurotransmission (main inhibitory pathway in CNS)

B. Sodium Channel Inhibition

• Blocks voltage-gated Na⁺ channels → reduces neuronal excitability

C. T-type Calcium Channel Inhibition

• Inhibits low-threshold (T-type) Ca²⁺ channels, particularly in thalamic neurons → effective against absence seizures

D. Histone Deacetylase Inhibition (HDACi)

• Epigenetic modulation → neuroprotective and anti-inflammatory effects

E. Other Effects

• May modulate glutamate transmission

• Reduces neuronal firing synchrony in epileptic foci

---

3. Spectrum of Anticonvulsant Activity

Fatty acid derivative anticonvulsants are broad-spectrum AEDs effective against both generalized and focal seizures.

Seizure Type	Efficacy of Valproate
Generalized tonic-clonic	Effective
Absence seizures	Highly effective
Myoclonic seizures	Effective
Atonic seizures	Effective
Focal (partial) seizures	Moderate–effective
Status epilepticus	IV valproate is used

Valproate is particularly effective in generalized epilepsies, especially in juvenile myoclonic epilepsy (JME) and Lennox–Gastaut syndrome.

---

4. Clinical Indications

A. Epilepsy (all ages)

• Monotherapy or adjunctive therapy for:

  • Generalized seizures

  • Partial seizures

  • Absence seizures

  • Myoclonic and atonic seizures

  • Infantile spasms (off-label)

B. Status Epilepticus

• IV valproate is an alternative to benzodiazepines, fosphenytoin, or levetiracetam

C. Bipolar Disorder

• Acute manic and mixed episodes

• Maintenance treatment (off-label in some regions)

D. Migraine Prophylaxis

• FDA-approved for preventing migraine headaches (not for acute treatment)

E. Off-label and Experimental Uses

• Schizoaffective disorder

• Aggression in dementia

• Neuropathic pain

• PTSD (limited evidence)

---

5. Pharmacokinetics

Parameter	Value/Details
Absorption	Rapid and complete (oral bioavailability ~90%)
Peak levels	1–4 hrs (immediate release), 6–12 hrs (ER)
Protein binding	~90% (non-linear, saturable)
Volume of distribution	~0.1–0.4 L/kg
Half-life	Adults: ~9–16 hours (longer in neonates, elderly)
Metabolism	Hepatic via glucuronidation (50%) and mitochondrial β-oxidation (40%)
Excretion	1–3% unchanged in urine

Note: The drug has non-linear kinetics, especially at higher doses due to protein-binding saturation.

---

6. Therapeutic Drug Monitoring (TDM)

Parameter	Target Range
Total serum valproate	50–100 mcg/mL (epilepsy)
Mania	50–125 mcg/mL
Toxicity threshold	>150 mcg/mL (risk increases significantly above 150–200 mcg/mL)

Levels should be interpreted in clinical context, especially in cases of hypoalbuminemia.

---

7. Adverse Effects

A. Common

• Gastrointestinal: nausea, vomiting, anorexia

• Sedation, tremor

• Weight gain

• Hair thinning or loss

• Menstrual irregularities

B. Hepatic

• Hepatotoxicity (black box warning), especially in children <2 years and with polytherapy

• Monitor AST, ALT, bilirubin regularly

C. Pancreatitis

• Life-threatening; can occur at any time

• Symptoms: abdominal pain, vomiting, elevated serum amylase/lipase

D. Hematologic

• Thrombocytopenia

• Leukopenia

• Platelet dysfunction (prolonged bleeding time)

E. Metabolic

• Hyperammonemia (even without liver dysfunction)

• Encephalopathy associated with carnitine deficiency

• Polycystic ovary syndrome (PCOS) in adolescent girls

F. Teratogenicity

• Highly teratogenic: Neural tube defects (NTDs), autism spectrum disorder, reduced IQ

• Boxed warning: Do not use in pregnancy for migraine prophylaxis and avoid in epilepsy or bipolar disorder unless no alternatives exist

G. CNS

• Dose-related tremor

• Ataxia

• Confusion

---

8. Contraindications

• Known hypersensitivity to valproate

• Pregnancy (migraine prophylaxis—absolute contraindication; epilepsy/bipolar—relative)

• Severe hepatic disease

• Urea cycle disorders

• Mitochondrial disease (e.g., Alpers-Huttenlocher syndrome)

---

9. Precautions and Monitoring

Monitoring Parameter	Frequency
Liver function (AST, ALT)	Baseline, then periodically
Ammonia levels	If mental status changes
CBC, platelets	Baseline and periodically
Valproate serum levels	As needed (toxicity/symptom)
Weight, BMI	Periodically
Pregnancy test (females)	Prior to initiation
Signs of pancreatitis	With GI symptoms

Counsel women of childbearing age about effective contraception and discuss risks.

---

10. Drug Interactions

Interacting Drug/Class	Interaction Mechanism	Clinical Implication
Phenytoin, Carbamazepine	Enzyme inducers; ↓ valproate levels	Reduced efficacy
Lamotrigine	Valproate inhibits metabolism → ↑ lamotrigine levels	↑ risk of SJS/TEN
Phenobarbital	Valproate inhibits metabolism → ↑ phenobarbital	Sedation, toxicity
Aspirin	Displaces valproate from albumin	↑ free valproate, potential toxicity
Warfarin	Inhibits metabolism and protein binding	↑ bleeding risk
Carbapenem antibiotics	↓ valproate levels via unknown mechanism	Loss of seizure control
Oral contraceptives	Valproate may alter estrogen metabolism	No significant reduction in contraceptive efficacy

11. Formulations and Dosing

A. Valproic Acid (Depakene)

• Oral capsules: 250 mg

• Oral solution: 250 mg/5 mL

• Typical dose: 10–15 mg/kg/day, titrate to 60 mg/kg/day max

B. Divalproex Sodium (Depakote)

• Delayed-release tablets: 125, 250, 500 mg

• Extended-release (ER): 250, 500 mg

• Initial dose: 10–15 mg/kg/day; target dose depends on clinical response

C. Sodium Valproate

• IV or oral; used interchangeably with VPA

Titration is essential to balance efficacy and side effect risk.

---

12. Clinical Considerations in Practice

• First-line for generalized epilepsies and mixed seizure types

• Avoid as first choice in women of childbearing potential

• Can be used in refractory epilepsy, status epilepticus, or bipolar mania

• Excellent for myoclonic and absence seizures where others (like carbamazepine) may worsen symptoms